Zeta INI-1 Antibody. Zeta’s mouse monoclonal antibody recognizes INI-1, a core subunit of the adenosine triphosphate (ATP) dependent SWI and SNF chromatin remodeling complex, which is actively involved in the regulation of gene expression. The INI-1 gene has been found to be a tumor suppressor, which is often mutated or deleted in malignant rhabdoid tumors, epithelioid sarcoma, and some malignant peripheral nerve sheath (MPNST) tumors.
The INI-1 protein (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1) encoded by the SMARCB1 gene. The INI-1 protein is part of a complex that relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively.
The INI-1 is a tumor supressor where loss of function is associated with rhabdoid tumor predisposition syndrome 1 and familial schwannomatosis and has been identified in a variety of rhabdoid and nonrhabdoid neoplasms of the CNS, soft tissue and parenchymal and visceral organs. Additionally, INI-1 loss of expression contributes to malignant rhabdoid tumor of kidney and soft tissue and CNS atypical teratoid or rhabdoid tumor and renal medullary carcinoma. INI-1 loss of function is found in sinonasal carcinoma or adenocarcinoma and undifferentiated and rhabdoid carcinoma of the gastrointestinal tract and pancreas.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.